This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National
by Zacks Equity Research
Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Buy These 5 Low Leverage Stocks to Strengthen Your Portfolio
by Zacks Equity Research
With the Q1 earnings season in its last lap, we would recommend investors to avoid high-leveraged stocks, even if they are exhibiting solid earnings growth.
Can Amedisys (AMED) Stock Continue to Grow Earnings?
by Zacks Equity Research
Amedisys (AMED) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth
by Zacks Equity Research
Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.
Healthcare Stocks' Earnings Due on May 7: EVHC, PINC & More
by Zacks Equity Research
Acute flu, aging population, increase in patient volumes and high claims would affect healthcare companies' Q1 earnings.
Amedisys (AMED) Up 1.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Envision Healthcare Divests AMR Unit, Streamlines Business
by Zacks Equity Research
Envision Healthcare (EVHC) divests its American Medical Response business to reduce leverage and focus on high-growth business.
5 Growth Stocks in MedTech Set to Scale Higher in 2018
by Zacks Equity Research
The U.S. MedTech markets have been riding high with merger and acquisitions in focus.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in fourth-quarter 2017.
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
by Zacks Equity Research
Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.
Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Amedisys (AMED) registers strong growth across all segments in Q4.
Amedisys (AMED) Strong on Home Health, Margin Decline a Woe
by Zacks Equity Research
Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.
Veeva Systems' Product Portfolio Strong, Competition Rife
by Zacks Equity Research
Veeva Systems (VEEV) rides on growing demand for cloud-based and vault applications. However, the company faces cutthroat competition in the niche space.
Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abaxis (ABAX) rides high on recently received approval from USDA.
Intuitive Surgical Gains on FDA Approvals, Competition Rife
by Zacks Equity Research
Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.
Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from revenue growth in Instrument & Accessories plus Services and Systems segments in Q4.
PerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 Guidance
by Zacks Equity Research
Solid performance in Discovery & Analytical Solutions segment drives PerkinElmer (PKI) in Q4. A strong guidance for FY18 instills investor's optimism.
Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance
by Zacks Equity Research
Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.
Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q2.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
Walgreens Boots' Retail Pharmacy Strong, Competition Rife
by Zacks Equity Research
Walgreens Boots (WBA) rides high on continued prescription growth and strength in the Retail Pharmacy USA division.
PetMed (PETS) Q3 Earnings Top Estimates, Reorder Sales Solid
by Zacks Equity Research
The upside in third-quarter fiscal 2018 sales at PetMed (PETS) is a result of the significant increase in new orders and reorder sales.
ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.
Medtronic's FDA Nod for Riptide Aspiration System Boosts RTG
by Zacks Equity Research
Medtronic (MDT) makes efforts to boost RTG business.